TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33645135
Drug: Honghua Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honghua Injection combined with conventional treatment
Study: 32471400
Drug: A Healthy
Normalized name: Neutrogena Healthy Scalp Conditioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Healthy Generation programme (physical activity and healthy meals/fruit twice a week from August to May)
Study: 32331079
Drug: Dasotraline (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline (4-8 mg/d)
Study: 35304391
Drug: Monthly online
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly online ePROM symptom reporting
Study: 37368349
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV)
Study: 32107360
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all 3 antagonists (BCTC, A‐967079, amiloride)
Study: 32281732
Drug: Diet soda
Normalized name: Magadi soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet soda containing sucralose and acesulfame‐potassium (Ace‐K) consumed three times daily for 8 weeks
Study: 35045221
Drug: Chemotherapy (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (doxorubicin at 60 mg/m² every 3 weeks or paclitaxel at 80 mg/m² weekly)
Study: 34108078
Drug: Sufentanil 1.91
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1.91 μg (ED90)
Study: 34108078
Drug: Sufentanil 2
Normalized name: SUFentanil 250 MCG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2 μg (recommended dosage)
Study: 33303468
Drug: Functional avoidance
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional avoidance radiation therapy
Study: 35315622
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion
Study: 32439205
Drug: Pseudomonas aeruginosa
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas aeruginosa spray
Study: 35440940
Drug: Routine oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oxygen therapy combined with NIV (low flow conventional oxygen therapy + NIV)
Study: 35440940
Drug: Routine oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oxygen therapy combined with NIV
Study: 33472779
Drug: Individuals with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals with knowledge of hypertension consequences and treatment options
Study: 33472779
Drug: Individuals who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals who believed BP medications should be stopped from time to time
Study: 33472779
Drug: Individuals who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals who reported not taking daily treatment
Study: 33472779
Drug: Individuals listing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals listing BP medications as the most effective way to reduce BP
Study: 32280083
Drug: Oral omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Study: 36095308
Drug: Progesterone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (up to 400 mg/day)
Study: 35126618
Drug: Tuina therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina therapy
Study: 34270348
Drug: MIBG +
Normalized name: mIBG
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIBG + Vincristine (IV on day 0) + Irinotecan (daily on days 0-4)
Study: 34270348
Drug: MIBG +
Normalized name: mIBG
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIBG + Vorinostat (180 mg/m2/dose orally once daily on days 1 to 12)
Study: 32690001
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) - single dose (wavelength 830nm, energy 2J/point) applied at four points (2 buccal, 2 palatal) for each maxillary anterior tooth root.
Study: 32690001
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment - same application procedure without emitting the laser beam.
Study: 35422183
Drug: Glyphosate low
Normalized name: glyphosate
DrugBank: Glyphosate (DB04539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate low dose of 7.2 g a.e. ha‐1
Study: 35422183
Drug: Glyphosate low
Normalized name: glyphosate
DrugBank: Glyphosate (DB04539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate low dose of 108.0 g a.e. ha‐1
Study: 35633275
Drug: Solriamfetol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 300 mg/day
Study: 32250572
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care tablet containing kiwifruit powder (Intervention II)
Study: 32250572
Drug: Three oral
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three oral care tablets (Intervention III)
Study: 32585854
Drug: Almega®PL (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almega®PL (1 g/day)
Study: 36071165
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy matched to genomic alteration
Study: 34538087
Drug: Monitoring group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring group (platelet function monitoring-guided adjustment of antiplatelet therapy)
Study: 37257216
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg/day for 14 days, then tapered to 10 mg for 1 month, followed by 5 mg/day for 2 months.
Study: 37257216
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg/day for 14 days, then tapered to 5 mg for 2 months.
Study: 34444526
Drug: Variable-rate feedback
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-rate feedback infusion (VFIM) of fentanyl/ropivacaine, basal infusion rate adjusted by 0.5 mL/h increase and 0.3 mL/h decrease
Study: 34444526
Drug: Conventional fixed-rate
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fixed-rate basal infusion (CFIM) of fentanyl/ropivacaine, fixed basal infusion rate of 5 mL/h
Study: 32234755
Drug: AZD9496 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9496 250 mg twice daily for 5-14 days
Study: 32234755
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg on day 1
Study: 38101250
Drug: Treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual
Study: 32751219
Drug: High polyphenol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyphenol olive oil (HPOO) - 60 mL/day (360 mg/kg polyphenols)
Study: 32751219
Drug: Low polyphenol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low polyphenol olive oil (LPOO) - 60 mL/day (86 mg/kg polyphenols)
Study: 33576820
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (50 mg)
Study: 35194193
Drug: Anthracycline/cyclophosphamide‐taxane‐containing chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline/cyclophosphamide‐taxane‐containing chemotherapy (AC‐T)
Study: 33814250
Drug: Corticocancellous (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticocancellous (CC) grafting
Study: 32538252
Drug: MDMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (100 mg MDMA-HCl)
Study: 34666854
Drug: CGMP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGMP (20 g)
Study: 34024503
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester supplement
Study: 34137904
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dextroamphetamine
Study: 34836025
Drug: Tocovid (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocovid (200 mg twice daily)
Study: 36267362
Drug: CONT-MMI (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONT-MMI (continuation of low-dose methimazole therapy at 2.5-5 mg/day)
Study: 36267362
Drug: DISCONT-MMI (discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DISCONT-MMI (discontinuation of low-dose methimazole therapy)
Study: 35793833
Drug: Lenzilumab (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenzilumab (1800 mg; three divided doses, q8h, within 24 hours)
Study: 36223695
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab into the thigh
Study: 36223695
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab into the abdominal wall (AW)
Study: 32630031
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (5‐methyl‐tetrahydrofolate: 15 mg/day)
Study: 32630031
Drug: 5 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/day of Oxo with 300 μg folic acid (oxifolic)
Study: 32630031
Drug: 5 mL/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/day of Oxo alone (magnesio+)
Study: 33821693
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intravenous Q4W
Study: 33821693
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg subcutaneous Q4W
Study: 33821693
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intravenous Q12W
Study: 33821693
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg subcutaneous Q12W
Study: 33821693
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg intravenous Q12W
Study: 33821693
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg subcutaneous Q12W
Study: 34609773
Drug: Depatuxizumab mafodotin
Normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatuxizumab mafodotin plus chemotherapy (temozolomide) in second-line therapy for EGFR-amplified recurrent WHO grade III/IV glioma
Study: 34609773
Drug: Depatuxizumab mafodotin
Normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatuxizumab mafodotin alone in second-line therapy for EGFR-amplified recurrent WHO grade III/IV glioma
Study: 34609773
Drug: Depatuxizumab mafodotin
Normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatuxizumab mafodotin plus chemoradiotherapy in first-line therapy for newly diagnosed WHO grade III/IV glioma
Study: 34609773
Drug: Depatuxizumab mafodotin
Normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatuxizumab mafodotin alone or plus chemotherapy/chemoradiotherapy
Study: 32028023
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% minoxidil gel
Study: 32028023
Drug: Topical 0.2%
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2% glyceryl trinitrate (GTN) cream
Study: 34455583
Drug: Bamlanivimab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab (700 mg, 2,800 mg, or 7,000 mg)
Study: 34971025
Drug: Tablet PC-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PC-based dementia training (control)
Study: 34836662
Drug: Clarithromycin-based standard
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based standard triple therapy (STT)
Study: 34836662
Drug: Susceptibility-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Susceptibility-guided therapy (SGT)
Study: 32931024
Drug: Hyperthermic intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS)
Study: 36083855
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonists (LTRA), specifically 10 mg of montelukast orally daily for 8 weeks.
Study: 33284719
Drug: Mefenpyr‐diethyl (50 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenpyr‐diethyl (50 g a.i. ha‐1) applied on soybean plants
Study: 32558469
Drug: Guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided treatment
Study: 32111264
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily for 6 months
Study: 34307140
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy group (sustained-release fluorouracil implants after standard D2 radical gastrectomy, followed by XELOX adjuvant chemotherapy)
Study: 34307140
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy group
Study: 36454580
Drug: Tucatinib in
Normalized name: Product containing tucatinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib in combination with trastuzumab and capecitabine
Study: 36454580
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with trastuzumab and capecitabine
Study: 35608017
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral minocycline 100 mg per day plus NBUVB phototherapy
Study: 38662979
Drug: Vidofludimus calcium
Normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidofludimus calcium 45 mg
Study: 38662979
Drug: Vidofludimus calcium
Normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidofludimus calcium 30 mg
Study: 32493029
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 µg/kg
Study: 33059613
Drug: Supplemental drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental drugs (iron folate)
Study: 32744040
Drug: Baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (no treatments)
Study: 35425986
Drug: Family Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Centered Advance Care Planning for Teens with Cancer (FACE‐TC); 3 weekly sessions
Study: 33661716
Drug: Control (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (licensed tetanus, diphtheria, and acellular pertussis vaccine)
Study: 33661716
Drug: Control (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (23-valent polysaccharide vaccine)
Study: 35753838
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (separate administration)
Study: 33356449
Drug: Various delivery
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various delivery routes (oral, intradermal, intravenous)
Study: 34551495
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 4 ml/kg (group V1)
Study: 34551495
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 5 ml/kg (group V2)
Study: 35288477
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg subcutaneous dose)
Study: 33258354
Drug: Flesh-moistening paste
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesh-moistening paste applied topically twice daily for eight weeks
Study: 33258354
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied topically twice daily for eight weeks
Study: 34330462
Drug: REPLENISH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: REPLENISH group (target protein 1.8-2.2 g/kg/day)
Study: 34330462
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (target protein 0.8-1.0 g/kg/day)
Study: 35643253
Drug: Palliative standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative standard-of-care treatment
Study: 32535732
Drug: IL-6 inhibitors
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 inhibitors
Study: 38802811
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment
Study: 32621644
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d
Study: 32434237
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate combined with levobupivacaine periarticular cocktail (20 mL of magnesium sulfate 250 mg + levobupivacaine 50 mg + triamcinolone 25 mg + 0.9% normal saline)
Study: 33020647
Drug: LV20.19 CAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV20.19 CAR T cells (various doses)
Study: 32753113
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (bolus 10 mg kg−1)
Study: 32753113
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose + maintenance (bolus 10 mg kg−1 + maintenance 1 mg kg−1 hr−1)
Study: 32753113
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (bolus 30 mg kg−1)
Study: 32753113
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose + maintenance (bolus 30 mg kg−1 + maintenance 3 mg kg−1 hr−1)
Study: 32572490
Drug: ePRO smartphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePRO smartphone app for RA (RA App v.1.0) with daily notifications regarding ePROs
Study: 35352593
Drug: tolcapone 300
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tolcapone 300 mg/day
Study: 33033800
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil
Study: 34402044
Drug: Facemask oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask oxygen (15 l.min-1)
Study: 34402044
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (50 l.min-1)
Study: 34378456
Drug: Laquinimod 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.6 mg
Study: 35487730
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily
Study: 33305662
Drug: Cabergoline combined
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline combined with hormone therapy standard schemes
Study: 35791704
Drug: Dexpanthenol ampoule
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol ampoule 250 mg/2 ml and biotin ampoule 5 mg/1 ml (Pars Behvarzan)
Study: 35791704
Drug: Dexpanthenol ampoule
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol ampoule 250 mg/2 ml and biotin ampoule 5 mg/1 ml (Bayer Company)
Study: 35334797
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (75 mg of Cr monohydrate·kg−1·day−1)
Study: 34704430
Drug: Ceratonia siliqua
Normalized name: CERATONIA SILIQUA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceratonia siliqua (Carob) capsules, 500 mg, taken daily for 90 days
Study: 34704430
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E capsules, taken three times a day for 90 days
Study: 35975547
Drug: High-dose AD109
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AD109 (75/2.5 mg)
Study: 35975547
Drug: Low-dose AD109
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AD109 (37.5/2.5 mg)
Study: 34321048
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d whole meat GSM powder
Study: 32546963
Drug: Apatinib (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (750 mg daily from Day 9-21)
Study: 38458796
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCB)
Study: 32289853
Drug: Thrombin injection
Normalized name: factor IX / factor VII / factor X / protein C / protein S / prothrombin Injection
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin injection
Study: 32289853
Drug: Glue injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glue injection
Study: 34641839
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation program (including occupational therapy and reintegration consultation)
Study: 34238342
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) granules combined with chemotherapy
Study: 32437567
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg per day plus Biejia-Ruangan (BR) 2 g 3 times a day for 72 weeks
Study: 32437567
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg per day plus Biejia-Ruangan (BR)